Verition Fund Management
ZYNE

Verition Fund Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Verition Fund Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,078
Closed -$15K – 2986
2022
Q3 		$15K Sell
20,078
-10,603
-35% -$12K ﹤0.01% 2833
2022
Q2 		$35K Buy
+30,681
New +$39.1K ﹤0.01% 2181
2020
Q3 		– Sell
-10,000
Closed -$34K – 1437
2020
Q2 		$34K Buy
+10,000
New +$47.3K ﹤0.01% 1027

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Verition Fund Management's ZYNE Position: Q4 2022 in Review

Verition Fund Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 20,078 shares — an estimated $15K sold.

Verition Fund Management first reported a position in ZYNE in Q2 2020 and held it in 3 quarters. The position peaked at $35K in Q2 2022. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Verition Fund Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Verition Fund Management sold 20,078 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $15K.
  • Verition Fund Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2020 and held it in 3 quarters.
  • Verition Fund Management's Zynerba Pharmaceuticals, Inc position peaked at $35K in Q2 2022.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.